目的：探讨重组组织型纤维蛋白溶酶原激活剂在治疗急性心肌梗死患者中的效果与价值。方法选取自2012年6月～2013年6月期间，住院部所收治的40例急性心肌梗死患者为研究对象，按照计算机随机方法进行分组，分成对照组、干预组，每组患者20例。对照组给予尿激酶治疗，干预组给予重组组织型纤维蛋白溶酶原激活剂治疗。对两组患者的治疗效果进行综合评估。结果干预组患者治疗总有效率为85.00%（17/20），明显高于对照组，死亡率明显低于对照组，数据对比差异具有统计学意义（P＜0.05）。结论重组组织型纤维蛋白溶酶原激活剂治疗急性心肌梗死疗效显著，可作为本病基础用药。%Objective To explore the recombinant tissue type fiber original activator protein enzyme in effect and value in the treatment of acute myocardial infarction patients.Methods From June 2012 to June 2013, during the inpatient admitted by 40 cases of patients with acute myocardial infarction (mi) as the research object, according to the computer random grouping, were divided into control group and intervention group, 20 cases of patients in each group. The control group given urokinase treatment, intervention group was given recombinant tissue type fiber original activator protein enzyme treatment. Therapeutic effect of two groups of patients with comprehensive evaluation.Results Intervention group patients treatment the total effective rate was 85.00%(17/20), significantly higher than the control group, mortality is significantly lower than the control group, the data contrast differences statistically significant (P<0.05).Conclusion Recombinant tissue type fiber original activator protein enzyme treatment of acute myocardial infarction curative effect significantly, can be used as the disease based drugs .
展开▼
